GlassScriptPhysician profile
James J Griffin
NPI 1255432894
$5,716.85
in general payments reported to CMS, 2019-2025
30 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $731 · 2021: $762 · 2022: $412 · 2023: $565 · 2024: $784 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,073.84 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,068.65 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,010.11 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $450.88 | 2019-2025 | Dupixent |
| Genzyme Corporation | $364.14 | 2022-2025 | |
| Amgen INC. | $329.94 | 2019-2021 | |
| Electromed, INC. | $234.57 | 2022-2025 | Smartvest |
| Lilly USA, LLC | $147.03 | 2019-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $123.60 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $101.47 | 2019-2022 | |
| Ucb, INC. | $97.53 | 2019-2021 | |
| Verona Pharma, INC. | $88.72 | 2025 | Ohtuvayre |
| Allergan, INC. | $82.75 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $71.28 | 2019-2023 | |
| United Therapeutics Corporation | $55.20 | 2024 | Tyvaso |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $48.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.78 | 2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $46.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.16 | 2019 | |
| Philips North America LLC | $39.26 | 2024 | (Ak6) Vest Therapy |
| Beta Bionics, INC. | $31.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ani Pharmaceuticals, INC. | $26.76 | 2023 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $26.41 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $17.11 | 2021 | |
| Viatris Specialty LLC | $15.97 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $15.60 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.50 | 2021 | |
| Inogen, INC. | $14.30 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Intercept Pharmaceuticals, INC. | $14.21 | 2020 | |
| Abbvie INC. | $13.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.